RxDoctor Payments Data

Gary Swain, MD

Family Medicine · Naples, FLNPI 1245296813

Payments from drug & device makers

$443in general payments, 2019–2025

Across 7 payments — averaging $63.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$222
  • Astellas Pharma US Inc$90
  • AbbVie$58
  • Arthrex$45
  • Merck$16
  • Amgen$12

What the payments were for

  • Travel & lodging$153%
  • Food & beverage$42897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$443 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$136,114
Medicare patients
219
Services billed
16,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$109,915
JardianceEmpagliflozin51$51,305
RybelsusSemaglutide26$50,411
XareltoRivaroxaban28$41,134
OzempicSemaglutide41$39,096
XifaxanRifaximin11$35,321
Repatha SureclickEvolocumab20$26,597
JanuviaSitagliptin Phosphate24$25,730
FarxigaDapagliflozin Propanediol16$19,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,379
Praluent PenAlirocumab17$12,916
MyrbetriqMirabegron20$12,074
TrulicityDulaglutide12$11,797
Rosuvastatin Calcium232$4,145
SynthroidLevothyroxine Sodium25$3,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$16$25,73024 claims
Astellas Pharma US IncMyrbetriq$90$12,07420 claims
AbbVieSynthroid$58$3,36225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →